Valuation: HitGen Inc.

Market Cap 14.49B 2.16B 1.85B 1.73B 1.58B 2.97B 206B 3.01B 20.41B 7.96B 104B 8.09B 7.92B 343B P/E 2026 *
106x
P/E 2027 * 83.1x
Enterprise Value 14.49B 2.16B 1.85B 1.73B 1.58B 2.97B 206B 3.01B 20.41B 7.96B 104B 8.09B 7.92B 343B EV / Sales 2026 *
22.7x
EV / Sales 2027 * 18.5x
Free-Float
50.43%
Yield 2026 *
0.24%
Yield 2027 * 0.41%
1 day-6.56%
1 week-6.42%
Current month+30.97%
1 month+27.77%
3 months+14.43%
6 months+22.78%
Current year+54.20%
1 week 34.96
Extreme 34.96
40.57
1 month 26.18
Extreme 26.18
41.78
Current year 22.42
Extreme 22.42
42.98
1 year 21.46
Extreme 21.46
42.98
3 years 8.35
Extreme 8.35
42.98
5 years 8.35
Extreme 8.35
42.98
10 years 8.35
Extreme 8.35
61.99
Manager TitleAgeSince
Chief Executive Officer 63 2012-05-31
Director of Finance/CFO 56 2023-04-26
Investor Relations Contact 38 2019-06-30
Director TitleAgeSince
Chairman 63 2012-05-31
Director/Board Member 73 2012-01-31
Director/Board Member 65 2019-03-23
Change 5-day change 1-year change 3-year change Capi.($)
-6.56%-6.42%+59.15%+145.99% 2.16B
-3.00%+2.27%+73.26%+113.08% 72.12B
+1.90%+23.53%+59.48%+94.94% 65.85B
+5.12%+25.22%+5.13%-5.23% 29.28B
+0.55%+1.64%-4.63%+469.35% 27.47B
+2.74%+12.98%+54.92%+24.09% 26.7B
+0.47%+6.12%+37.01%-16.17% 20.06B
+1.82%-6.67%+251.36%+388.91% 18.22B
+0.94%+3.36%+15.30%+581.01% 16.4B
+0.73%+5.54%+39.99%+148.64% 13.4B
Average +0.47%+6.95%+59.10%+194.46% 29.16B
Weighted average by Cap. +0.69%+9.37%+58.03%+159.05%

Financials

2026 *2027 *
Net sales 638M 94.9M 81.29M 76.06M 69.62M 131M 9.08B 132M 899M 350M 4.56B 356M 349M 15.09B 781M 116M 99.53M 93.13M 85.25M 160M 11.12B 162M 1.1B 429M 5.58B 436M 427M 18.47B
Net income 137M 20.37M 17.45M 16.33M 14.95M 28.05M 1.95B 28.42M 193M 75.23M 979M 76.49M 74.83M 3.24B 174M 25.9M 22.19M 20.76M 19M 35.66M 2.48B 36.14M 245M 95.65M 1.24B 97.26M 95.14M 4.12B
Net Debt - -
Logo HitGen Inc.
HitGen Inc is a China-based company primarily engaged in the research, development and optimization of small molecule and nucleic acid-based new drug candidates using deoxyribonucleic acid (DNA) encoded chemical library (DEL) technology. Through the drug discovery and optimization platform, the Company provides clients with services such as screening and optimization of designated biological targets, customized DEL design and synthesis, synthesis and modification of certain designated compounds or nucleic acids and related biological evaluation. The Company is also engaged in the transfer of rights and interests in new drug research projects, capital operations and marketing activities. The Company primarily operates its businesses in the domestic market and overseas markets, including the United States, France, the United Kingdom and Japan.
Employees
546
Date Price Change Volume
26-08-21 CN¥36.16 -6.56% 24,474,052
26-08-20 CN¥38.70 +10.10% 32,593,295
26-08-19 CN¥35.15 -6.66% 20,723,868
26-08-18 CN¥37.66 -1.90% 16,372,491
26-08-17 CN¥38.39 -0.65% 21,733,868
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
36.16CNY
Average target price
31.60CNY
Spread / Average Target
-12.61%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 688222 Stock